+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Artificial Intelligence in Drug Discovery Market - Global Forecast 2026-2032- Product Image
Artificial Intelligence in Drug Discovery Market - Global Forecast 2026-2032- Product Image
Sale

Artificial Intelligence in Drug Discovery Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4995111
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Artificial Intelligence in Drug Discovery Market is projected to reach USD 3.03 Billion in 2026. It is expected to continue growing at a CAGR of 23.07%, reaching USD 10.66 Billion by 2032.

Artificial intelligence in drug discovery has moved from experimental use cases to a core R&D capability across target identification, hit discovery, lead optimization, ADMET prediction, biomarker discovery, and clinical trial design. The shift is supported by validated scientific milestones, including the AlphaFold Protein Structure Database covering more than 200 million predicted protein structures, the U.S. FDA’s ongoing work on AI and machine learning in drug development, and the growing use of high-performance cloud computing in life sciences.

For pharmaceutical companies, biotechnology firms, contract research organizations, and technology partners, AI is not a replacement for biology, chemistry, or clinical evidence. Its strongest value is in compressing hypothesis cycles, improving decision quality, and prioritizing compounds and patient populations before expensive wet-lab or clinical investments are made.

Transformative Shifts in the AI Drug Discovery Landscape

The drug discovery landscape is shifting from sequential, lab-intensive workflows to integrated computational-experimental models. Generative AI, graph neural networks, natural language processing, and multimodal foundation models are helping researchers analyze chemical libraries, omics datasets, protein structures, publications, patents, and real-world data at scale.

Regulatory and operating models are also changing. The U.S. FDA, EMA, and other agencies are increasing attention on model transparency, validation, data provenance, and risk management. At the same time, cloud infrastructure, secure data collaboration, and automation are enabling pharmaceutical R&D teams to evaluate more hypotheses while maintaining traceability and reproducibility.

Cumulative Impact of Artificial Intelligence on Drug R&D

The cumulative impact of artificial intelligence is most visible in earlier and more evidence-driven decision-making. AI-enabled platforms can help identify disease-relevant targets, screen virtual compound libraries, forecast toxicity, optimize molecular properties, and support patient stratification. These applications reduce avoidable experimentation and improve the quality of candidates moving into validation.

However, AI does not eliminate scientific uncertainty. Drug attrition remains driven by complex biology, safety, efficacy, manufacturability, and clinical execution. The organizations gaining the greatest advantage are those combining high-quality proprietary data, rigorous model governance, laboratory validation, and cross-functional teams spanning biology, chemistry, informatics, clinical development, and regulatory affairs.

Key Regional Insights: North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa

North America leads AI-enabled drug discovery through a dense ecosystem of pharmaceutical companies, AI-native biotechnology firms, academic medical centers, cloud providers, venture capital, and regulatory engagement. The United States benefits from NIH-funded biomedical research, FDA digital health and AI initiatives, and a large clinical trial infrastructure, while Canada’s long-standing AI research base and biomedical clusters strengthen translational innovation.

Europe is advancing through strong public research, biopharmaceutical manufacturing, and regulatory modernization, including the EU AI Act and European Health Data Space framework. Asia-Pacific is scaling rapidly, with China, Japan, India, South Korea, Singapore, and Australia investing in genomics, precision medicine, computational biology, and biomanufacturing. Latin America is emerging through Brazil and Mexico’s clinical research capacity, public health datasets, and pharmaceutical manufacturing foundations, while the Middle East is investing in genomics, digital health, and precision medicine through national strategies in the UAE, Saudi Arabia, and other Gulf economies. Africa’s opportunity is tied to genomic diversity, infectious disease research, local biobank development, and capacity-building programs that can improve global model generalizability and reduce data bias in AI drug discovery.

Key Group Insights: EU, G7, BRICS, ASEAN, GCC, and NATO

The European Union is becoming a reference market for trustworthy AI in life sciences, combining advanced research networks with strict rules on data protection, clinical evidence, and algorithmic accountability. G7 countries continue to shape global standards through pharmaceutical R&D intensity, academic excellence, intellectual property systems, regulatory science coordination, and cross-border collaboration on health security.

BRICS economies are strategically important because of their population scale, expanding clinical research networks, manufacturing capacity, and increasing investment in AI, genomics, and biotechnology. ASEAN is gaining relevance through Singapore-led biomedical innovation, regional digital health adoption, and growing clinical research activity across Southeast Asia, while the GCC is using national health transformation programs, population genomics initiatives, and advanced hospital infrastructure to accelerate precision medicine. NATO member countries also influence the sector indirectly through biosecurity, resilient supply chains, cybersecurity, trusted data infrastructure, and dual-use technology governance that affect AI-enabled biomedical innovation.

Key Country Insights Across Major AI Drug Discovery Markets

The United States remains the most influential country for AI in drug discovery due to its concentration of pharmaceutical R&D, venture-backed AI biotechnology companies, FDA engagement, NIH-supported biomedical research, and leading academic medical centers. Canada contributes world-class machine learning expertise and translational AI hubs, while Mexico and Brazil strengthen the Americas through clinical research access, pharmaceutical production capabilities, public health institutions, and growing digital health adoption.

In Europe, the United Kingdom combines biomedical research excellence, national health data assets, and a strong AI startup ecosystem; Germany leads in pharmaceutical manufacturing, engineering, applied research, and industrial automation; France supports AI and health innovation through national investment programs and biomedical research networks; Italy and Spain offer strong clinical trial networks, hospital systems, and translational medicine capabilities; and Russia retains scientific capacity in chemistry, mathematics, and computational research despite geopolitical and collaboration constraints. In Asia-Pacific, China’s scale in data infrastructure, AI investment, genomics, and biopharma innovation is significant; India combines pharmaceutical manufacturing, digital public infrastructure, bioinformatics talent, and software engineering depth; Japan offers advanced precision medicine, robotics, and aging-related biomedical research capabilities; Australia has strong clinical research, genomics programs, and biomedical science institutions; and South Korea is expanding rapidly through government-backed biohealth, hospital digitalization, semiconductor strength, and AI initiatives.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize AI use cases with measurable scientific and operational value, such as target validation, virtual screening, toxicity prediction, protein structure analysis, biomarker discovery, and trial enrichment. Building a defensible advantage requires proprietary datasets, interoperable data architecture, model validation protocols, bias monitoring, cybersecurity controls, and clear documentation aligned with regulatory expectations.

Should also invest in human-AI operating models. The highest-performing organizations embed computational scientists with medicinal chemists, biologists, clinicians, and regulatory experts. Partnerships with AI biotechnology firms, cloud providers, universities, and CROs should be structured around data rights, reproducibility, auditability, model ownership, privacy protection, and milestone-based outcomes rather than technology adoption alone.

Research Methodology

This executive summary is based on a structured secondary research approach using verified public information from regulatory agencies, scientific institutions, government programs, peer-reviewed literature, public disclosures, and recognized life sciences databases. Key themes were triangulated across AI drug discovery workflows, regional innovation systems, regulatory developments, scientific adoption, and investment patterns.

The analysis emphasizes evidence-backed trends rather than speculative market claims. It evaluates how artificial intelligence is applied across discovery and development, where adoption is strongest, which regional ecosystems are gaining momentum, and what governance practices are needed to convert computational insights into validated therapeutic progress.

Conclusion: AI as a Strategic Engine for Modern Drug Discovery

Artificial intelligence is becoming a durable capability in drug discovery because it improves the speed, scale, and precision of scientific decision-making. Its greatest value is achieved when computational models are connected to reliable biological data, laboratory validation, clinical insight, and disciplined governance.

The landscape will be shaped by organizations that can combine AI innovation with regulatory credibility, proprietary data, and therapeutic domain expertise. As adoption expands across regions and industry groups, AI-enabled drug discovery is expected to remain one of the most important forces modernizing pharmaceutical R&D.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.1.1. Pressure to Improve R&D Productivity
4.3.1.2. Expansion of Biomedical Data
4.3.1.3. Model and Computing Advances
4.3.1.4. Strategic Biopharmaceutical Adoption
4.3.2. Key Restraints
4.3.2.1. Limited Comparable Outcome Evidence
4.3.2.2. Data Privacy and Access Constraints
4.3.2.3. High Implementation and Validation Costs
4.3.2.4. Persistent Biological and Clinical Uncertainty
4.3.3. Key Opportunities
4.3.3.1. Integrated Multimodal Discovery Systems
4.3.3.2. Expansion Beyond Small Molecules
4.3.3.3. Automated Design-Make-Test-Learn Workflows
4.3.3.4. Asia-Pacific Market Expansion
4.3.4. Key Challenges
4.3.4.1. Prospective Validation and Generalizability
4.3.4.2. Data Integration and Rights
4.3.4.3. Workflow and Organizational Integration
4.3.4.4. Capital Intensity and Long Validation Cycles
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Artificial Intelligence in Drug Discovery Market, by Offering
7.1. Introduction
7.2. Software Platforms
7.3. Discovery Services
8. Artificial Intelligence in Drug Discovery Market, by Discovery Workflow
8.1. Introduction
8.2. Hit Identification & Screening
8.3. Hit-to-Lead & Lead Optimization
8.4. Target Identification & Validation
8.5. Preclinical Candidate Assessment
9. Artificial Intelligence in Drug Discovery Market, by Therapeutic Modality
9.1. Introduction
9.2. Small-Molecule Therapeutics
9.3. Protein & Peptide Therapeutics
9.4. Nucleic-Acid Therapeutics
9.5. Combination & Conjugate Therapeutics
9.6. Cell-Based Therapeutics
10. Artificial Intelligence in Drug Discovery Market, by Data Foundation
10.1. Introduction
10.2. Chemical & Molecular Structure Data
10.3. Omics & Biological Sequence Data
10.4. Biomedical Text & Knowledge Graph Data
10.5. Imaging & Phenotypic Data
10.6. Clinical & Real-World Data
10.7. Integrated Multimodal Data
11. Artificial Intelligence in Drug Discovery Market, by End User
11.1. Introduction
11.2. Pharmaceutical & Biotechnology Companies
11.3. Contract Research & Development Organizations
11.4. Academic, Government & Nonprofit Research Institutions
12. Artificial Intelligence in Drug Discovery Market, by Region
12.1. North America
12.2. Europe
12.3. Asia-Pacific
12.4. Latin America
12.5. Middle East
12.6. Africa
13. Artificial Intelligence in Drug Discovery Market, by Group
13.1. NATO
13.2. G7
13.3. European Union
13.4. BRICS
13.5. ASEAN
13.6. GCC
14. Artificial Intelligence in Drug Discovery Market, by Country
14.1. United States
14.2. China
14.3. United Kingdom
14.4. Japan
14.5. Germany
14.6. Canada
14.7. France
14.8. India
14.9. Australia
14.10. South Korea
14.11. Brazil
14.12. Italy
14.13. Mexico
14.14. Spain
14.15. Russia
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Schrödinger, Inc.
16.2. Certara, Inc.
16.3. Dassault Systèmes SE
16.4. Insilico Medicine Cayman TopCo
16.5. Charles River Laboratories International, Inc.
16.6. Recursion Pharmaceuticals, Inc.
16.7. XtalPi Holdings Limited
16.8. Isomorphic Labs
16.9. NVIDIA Corporation
16.10. insitro
16.11. Valo Health, LLC
16.12. Causaly Ltd
16.13. Owkin Inc.
16.14. Genesis Molecular AI
16.15. AbCellera Biologics Inc.
16.16. Generate Biomedicines, Inc.
16.17. Aqemia
16.18. BenevolentAI
16.19. Iambic Therapeutics, Inc.
16.20. Iktos
16.21. Immunai Inc.
16.22. SandboxAQ
16.23. Terray Therapeutics, Inc.
16.24. Verge Analytics, Inc.
16.25. Atomwise Inc.
16.26. Deep Genomics Incorporated
16.27. Standigm
16.28. Pathos AI, Inc.
16.29. Relation Therapeutics Limited
16.30. Healx Ltd.
16.31. Enveda Therapeutics, Inc.
16.32. EvolutionaryScale
16.33. Chai Discovery, Inc.
16.34. Xaira Therapeutics, Inc.
16.35. Absci Corporation
16.36. Lantern Pharma Inc.
List of Figures
FIGURE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL SOFTWARE PLATFORMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL SOFTWARE PLATFORMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL SOFTWARE PLATFORMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL DISCOVERY SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL DISCOVERY SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL DISCOVERY SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL HIT IDENTIFICATION & SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL HIT IDENTIFICATION & SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL HIT IDENTIFICATION & SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL HIT-TO-LEAD & LEAD OPTIMIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL HIT-TO-LEAD & LEAD OPTIMIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL HIT-TO-LEAD & LEAD OPTIMIZATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL TARGET IDENTIFICATION & VALIDATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL TARGET IDENTIFICATION & VALIDATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL TARGET IDENTIFICATION & VALIDATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL PRECLINICAL CANDIDATE ASSESSMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL PRECLINICAL CANDIDATE ASSESSMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL PRECLINICAL CANDIDATE ASSESSMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL SMALL-MOLECULE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL SMALL-MOLECULE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL SMALL-MOLECULE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PROTEIN & PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PROTEIN & PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PROTEIN & PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL NUCLEIC-ACID THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL NUCLEIC-ACID THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL NUCLEIC-ACID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL COMBINATION & CONJUGATE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL COMBINATION & CONJUGATE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL COMBINATION & CONJUGATE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL CELL-BASED THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CELL-BASED THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CELL-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CHEMICAL & MOLECULAR STRUCTURE DATA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL CHEMICAL & MOLECULAR STRUCTURE DATA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL CHEMICAL & MOLECULAR STRUCTURE DATA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL OMICS & BIOLOGICAL SEQUENCE DATA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL OMICS & BIOLOGICAL SEQUENCE DATA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL OMICS & BIOLOGICAL SEQUENCE DATA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL BIOMEDICAL TEXT & KNOWLEDGE GRAPH DATA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL BIOMEDICAL TEXT & KNOWLEDGE GRAPH DATA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL BIOMEDICAL TEXT & KNOWLEDGE GRAPH DATA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL IMAGING & PHENOTYPIC DATA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL IMAGING & PHENOTYPIC DATA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL IMAGING & PHENOTYPIC DATA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL CLINICAL & REAL-WORLD DATA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL CLINICAL & REAL-WORLD DATA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CLINICAL & REAL-WORLD DATA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL INTEGRATED MULTIMODAL DATA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL INTEGRATED MULTIMODAL DATA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL INTEGRATED MULTIMODAL DATA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL CONTRACT RESEARCH & DEVELOPMENT ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL CONTRACT RESEARCH & DEVELOPMENT ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CONTRACT RESEARCH & DEVELOPMENT ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ACADEMIC, GOVERNMENT & NONPROFIT RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ACADEMIC, GOVERNMENT & NONPROFIT RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ACADEMIC, GOVERNMENT & NONPROFIT RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 71. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 72. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 73. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 74. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 75. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 77. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 78. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 79. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 80. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 87. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 89. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 90. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 91. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 92. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 93. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 95. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 96. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 97. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 98. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 99. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 101. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 102. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 103. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 104. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 108. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 109. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 110. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 111. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 112. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 114. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 115. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 116. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 117. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 118. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 120. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 121. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 122. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 123. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 124. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 126. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 127. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 128. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 129. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 130. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 132. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 133. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 134. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 135. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 136. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 137. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 138. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 139. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 140. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 141. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 143. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 144. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 145. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 146. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 147. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 148. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 149. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 150. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 151. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 152. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 153. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 154. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 155. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 156. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 157. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 158. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 159. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 160. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 161. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 162. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 163. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 164. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 165. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 166. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 167. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 168. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 169. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 170. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 171. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 172. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 174. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 175. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 176. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 177. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 178. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 179. FRANCE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 180. FRANCE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 181. FRANCE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 182. FRANCE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 183. FRANCE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 184. FRANCE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 185. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 186. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 187. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 188. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 189. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 190. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 191. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 192. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 193. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 194. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 195. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 196. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 197. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 198. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 199. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 200. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 201. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 202. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 203. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 204. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 205. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 206. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 207. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 208. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 209. ITALY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 210. ITALY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 211. ITALY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 212. ITALY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 213. ITALY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 214. ITALY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 215. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 216. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 217. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 218. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 219. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 220. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 221. SPAIN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 222. SPAIN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 223. SPAIN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 224. SPAIN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 225. SPAIN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 226. SPAIN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 227. RUSSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 228. RUSSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 229. RUSSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISCOVERY WORKFLOW, 2017-2032 (USD MILLION)
TABLE 230. RUSSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 231. RUSSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DATA FOUNDATION, 2017-2032 (USD MILLION)
TABLE 232. RUSSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 233. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2025
TABLE 234. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Schrödinger, Inc.
  • Certara, Inc.
  • Dassault Systèmes SE
  • Insilico Medicine Cayman TopCo
  • Charles River Laboratories International, Inc.
  • Recursion Pharmaceuticals, Inc.
  • XtalPi Holdings Limited
  • Isomorphic Labs
  • NVIDIA Corporation
  • insitro
  • Valo Health, LLC
  • Causaly Ltd
  • Owkin Inc.
  • Genesis Molecular AI
  • AbCellera Biologics Inc.
  • Generate Biomedicines, Inc.
  • Aqemia
  • BenevolentAI
  • Iambic Therapeutics, Inc.
  • Iktos
  • Immunai Inc.
  • SandboxAQ
  • Terray Therapeutics, Inc.
  • Verge Analytics, Inc.
  • Atomwise Inc.
  • Deep Genomics Incorporated
  • Standigm
  • Pathos AI, Inc.
  • Relation Therapeutics Limited
  • Healx Ltd.
  • Enveda Therapeutics, Inc.
  • EvolutionaryScale
  • Chai Discovery, Inc.
  • Xaira Therapeutics, Inc.
  • Absci Corporation
  • Lantern Pharma Inc.

Table Information

Report AttributeDetails
No. of Pages198
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.03 Billion
Forecasted Market Value ( USD ) by 2032 $ 10.66 Billion
Compound Annual Growth Rate23.0%
Regions CoveredGlobal
No. of Companies Mentioned36

Related Topics

Related Reports

Drug Discovery Market - Global Forecast 2026-2032 - Product Image

Drug Discovery Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Drug Discovery Outsourcing Market - Global Forecast 2026-2032 - Product Image

Drug Discovery Outsourcing Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
AI in Drug Screening - Global Strategic Business Report - Product Image

AI in Drug Screening - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
AI for Drug Development and Discovery - Global Strategic Business Report - Product Image

AI for Drug Development and Discovery - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Generative AI in Drug Discovery Market Report 2026 - Product Image

Generative AI in Drug Discovery Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.